GERN Geron Corp.: Earnings per one share for the last 12 months

Geron Corporation (GERN) is developing the first telomerase inhibitor, attracting scientists with an innovative approach to blood treatment. The annual EPS (TTM) growth rate on the GURU.Markets dynamic chart confirms this trajectory, with the value stabilizing at 37.70. Patent protection for the unique drug guarantees stable revenue, although the costs of promoting Rytelo in the US are temporarily weighing on the business's overall margins.
Geron Corp. - analytical breakdowns and key metrics (GERN)

Conservative capital demands maximum profit transparency to minimize risks when entering an asset. This indicator measures the daily rolling growth of net earnings per share over a year, allowing for the rapid capture of fundamental changes in business efficiency. For Geron Corporation (GERN), whose success depends on non-cyclical oncology research, the historical EPS YoY TTM delta serves as a precise filter for assessing financial stability prior to drug commercialization.